Newsroom

Digital screen with DNA data background. Nucleic acid sequence. Genetic research. 3d illustration.

September 27, 2023

Kriya Announces Exclusive License and Collaboration Agreement with Everads to Advance Gene Therapies for Prevalent Diseases in Ophthalmology Including Geographic Atrophy

: Kriya Announces Exclusive License and Collaboration Agreement with Everads to Advance Gene Therapies for Prevalent Diseases in Ophthalmology Including Geographic Atrophy
September 6, 2023

Kriya Acquires Tramontane Therapeutics and Launches Gene Therapy Program for Nonalcoholic Steatohepatitis (NASH) and Other Prevalent Diseases

: Kriya Acquires Tramontane Therapeutics and Launches Gene Therapy Program for Nonalcoholic Steatohepatitis (NASH) and Other Prevalent Diseases
July 26, 2023

Kriya Announces $150 Million Addition to its Series C, Bringing Total Round to over $430 Million to Further its Mission of Delivering Gene Therapies for Prevalent Diseases

: Kriya Announces $150 Million Addition to its Series C, Bringing Total Round to over $430 Million to Further its Mission of Delivering Gene Therapies for Prevalent Diseases
May 2, 2023

Kriya to Present 10 Abstracts at the 2023 American Society of Gene and Cell Therapy Annual Meeting

: Kriya to Present 10 Abstracts at the 2023 American Society of Gene and Cell Therapy Annual Meeting
November 16, 2022

Kriya Acquires Redpin Therapeutics, Adding Neurology Pipeline to Gene Therapy Portfolio

: Kriya Acquires Redpin Therapeutics, Adding Neurology Pipeline to Gene Therapy Portfolio
August 25, 2022

Kriya Appoints Curt Herberts as President and Chief Operating Officer

: Kriya Appoints Curt Herberts as President and Chief Operating Officer
May 16, 2022

Kriya Announces $270 Million Series C Financing to Advance Fully Integrated Gene Therapy Engine

: Kriya Announces $270 Million Series C Financing to Advance Fully Integrated Gene Therapy Engine
January 26, 2022

Kriya Licenses Next Generation Complement-Targeted Gene Therapies for the Treatment of Geographic Atrophy and Other Ocular Diseases

: Kriya Licenses Next Generation Complement-Targeted Gene Therapies for the Treatment of Geographic Atrophy and Other Ocular Diseases
July 28, 2021

Kriya Therapeutics Completes Renovation of its Facility for Scalable Gene Therapy Manufacturing

: Kriya Therapeutics Completes Renovation of its Facility for Scalable Gene Therapy Manufacturing

Media Contacts

Kriya Therapeutics, Inc.
[email protected]
833-574-9289